Oncotarget Amivantamab Monotherapy in Rare EGFR-Mutated Advanced NSCLC Amivantamab, an anti-EGFR/MET bispecific antibody, shows efficacy in EGFR-mutated NSCLC, but its role in... read more August 26, 2025
